Effects of Smoking and Vitamin D3 on the Levels of Human Cathelicidin Peptide LL-37
Evaluation of Gingival Crevicular Fluid Levels of LL-37 and Serum Vitamin D3 Levels in Smoker and Non-Smoker Patients With Chronic Periodontitis
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Background: Cathelicidin LL-37, an antimicrobial peptide, is part of the host innate immune response in the oral cavity. The aims of this study are to evaluate; gingival crevicular fluid (GCF) levels of LL-37, serum vitamin D3 levels and periodontal clinical recordings in smoker and nonsmoker patients with chronic periodontitis (CP).
Methods:
This study consisted a total of 60 volunteers including 20 smoker patients with CP (CP-1 group), 20 non-smoker patients with CP (CP-2 group) and 20 periodontally healthy subjects (CTRL group). Prior to participation, the design and purpose of the research were explained to each subjects, and written informed consent form was obtained from 60 individuals before the study.
The periodontal status of the patients were determined by measuring the probing depth (PD), clinical attachment level (CAL), gingival index (GI), plaque index (PI) All clinical parameters were measured on six sites per tooth from the full-mouth teeth (mesiobuccal, distobuccal,midbuccal, mesiolingual, distolingual and midlingual) using a William's periodontal probe calibrated in millimeters by the same examiner. All samples were obtained on the day following clinical examinations of the individuals. The deepest six pockets site per individual were chosen for collection of GCF across both of the periodontitis groups. Six pocket locations showing a lack of clinical inflammation were also tested to guarantee collection of a sufficient volume of GCF across the CTRL groups.
GCF levels of LL-37 were measured by ELISA and serum levels of vitamin D3 were analysed by High-performance liquid chromatography (HPLC). Statistical analysis were performed.
Studientyp
Einschreibung (Tatsächlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria for chronic periodontitis groups:
- Clinical attachment loss ≥ 5mm
- Probing depth ≥5mm
- Bone loss affecting >30% of the existing teeth on clinical and radiographic examination
- gingival index (GI) score> 1
Inclusion criteria for control group:
- full-mouth PD was≤ 3mm,
- Gingival index <1
- there was no indication of Attachment Loss or no radiographic evidence of alveolar bone loss in control group.
- Non-smokers.
Smoking criteria for groups:
- patients smoked more than 10 cigarettes in a day
- smoking for 3 or more years,
Exclusion Criteria:
- systemic condition (diabetes, cardiovascular disease, immunologic disorders, hepatitis, e.g.)
- pregnancy, lactation or menopause term,
- antibiotic treatment or non-steroidal anti-inflammatory medications within the last 3 months before the study,
- non-surgical periodontal treatment during the last 6 months before the study,
- treatment with Vitamin D supplementation before the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Smoker patients with chronic periodontitis
|
Collected gingival crevicular fluid
Collected serum
Recorded plague index, gingival index, probing depth, clinical attachment level
|
|
non-smoker patients with chronic periodontitis
|
Collected gingival crevicular fluid
Collected serum
Recorded plague index, gingival index, probing depth, clinical attachment level
|
|
periodontally healthy patients
|
Collected gingival crevicular fluid
Collected serum
Recorded plague index, gingival index, probing depth, clinical attachment level
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Serum D3 Vitamin levels
Zeitfenster: Baseline
|
The plasma levels of vitamin D3 were greater in the CP-2 group than in the CP-1 group.
But, no statistically significant difference was determined between the CP groups (P>0.05)
|
Baseline
|
|
Gingival Crevicular fluid(GCF) LL-37 levels
Zeitfenster: Baseline
|
The concentration of LL-37 in GCF was significantly higher in both of the CP groups than in the CTRL group (p<0.001).
Although GCF LL-37 concentration levels were greater in the CP-1 group than in the CP-2 group, the difference did not reach the statistical significance between the CP groups (p>0.05).
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Plaque index (PI)
Zeitfenster: Baseline
|
The full-mouth and sample sites PI recordings were significantly higher in both CP groups (CP-1 and CP-2) than in the CTRL group (p<0.001). were measured on six sites per tooth from the full-mouth teeth |
Baseline
|
|
GCF volume
Zeitfenster: Baseline
|
The GCF volume was notably higher in both CP groups than in CTRL group (p<0.001).
|
Baseline
|
|
gingival index (GI)
Zeitfenster: Baseline
|
The full-mouth and sample sites GI recordings were significantly higher in both CP groups (CP-1 and CP-2) than in the CTRL group (p<0.001).
|
Baseline
|
|
Probing depth (PD)
Zeitfenster: Baseline
|
The full-mouth and sample sites PD recordings were significantly higher in both CP groups (CP-1 and CP-2) than in the CTRL group (p<0.001).
|
Baseline
|
|
Clinical attachment level (CAL)
Zeitfenster: Baseline
|
The full-mouth and sample sites CAL recordings were significantly higher in both CP groups (CP-1 and CP-2) than in the CTRL group (p<0.001).
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Şeyma BOZKURT DOĞAN, Professor, University
- Hauptermittler: Elifcan Kıvrak, PhD, University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 03/2011-27
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .